Evaluation of the undifferentiated maintenance ability of a dimeric peptide composed of cyclic peptides that bind to human FGFR1c.
We present the results of evaluating the undifferentiated maintenance ability of FGF2 and the FGF2 alternative peptide "PG-011" using three types of human iPS cell lines. FGF2 (100 ng/mL, approximately 5.9 nM) or an equimolar concentration of PG-011 (approximately 30 ng/mL) was added to the culture medium, and after 7 days of culture, passaging was performed. Three passages were conducted, and the positive rate of undifferentiated markers in iPS cells on Day 7 of passage 3 (P3) was evaluated. As a result, the cell numbers at each passage were almost the same, confirming that "PG-011" exhibited similar proliferation ability to FGF2 in iPS cells. [Results] - iPS cells cultured with "PG-011" and FGF2 showed similar colony morphology. - The cell numbers at each passage were almost the same, confirming that "PG-011" exhibited similar proliferation ability to FGF2 in iPS cells. - The measurement results of undifferentiated markers in iPS cells on P3, Day 7 indicated that "PG-011" has an undifferentiated maintenance ability at the same level as FGF2. *For more detailed test results, please download the materials from the link below.
Inquire About This Product
basic information
【Other Evaluation Summary】 ■ Stability at 37℃ & Stability under Cell Culture Conditions ■ Cross-reactivity with Bovine Cells *If you would like to check more detailed test results, please download the materials from below.
Price range
Delivery Time
Applications/Examples of results
If you would like to check more detailed test results, please download the materials from below.
catalog（1）
Download All Catalogs
Company information
PepTigrowth Co., Ltd. is advancing the development of peptides known as "growth factor alternative peptides," which possess similar activity to conventional growth factors and cytokines, utilizing the unique technology held by its shareholder, PeptideRx. We are also capable of manufacturing at GMP-grade, intended for use in clinical trials for regenerative medicine and cell therapy. We will contribute to solving the challenges faced by the pharmaceutical industry and promoting the dissemination of cell therapy and regenerative medicine.